



# Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

2025-03-27

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events.

Highlights include:

- March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, “Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity and Alter the Tumor Microenvironment”
- March 17 to 19 – Participated in the BIO Europe conference in Milan, Italy
- April 29 to May 1 – Kairos is slated to participate at the Fierce Pharma Engage Business Development and Licensing Meeting in San Diego
- May 20 to June 5 – The American Society of Clinical Oncology (ASCO) has accepted an abstract to be presented at its Annual Meeting in Chicago
- March 27 – Maxim Group initiates research coverage of Kairos Pharma

"Kairos continues to gain momentum in both the scientific and business communities as we showcase the value of our diverse oncology programs. Our Phase 2 trials for ENV105 are progressing, while our KROS platform continues to demonstrate promising potential in cancer immunotherapy," said John Yu, M.D., CEO of Kairos Pharma. "We remain committed to advancing our developments alongside our partners, sharing our progress with the market, and driving long-term shareholder value."

## About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. ([NYSE American: KAPA](#)) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various

cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit [kairospharma.com](http://kairospharma.com).

## CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

CORE IR

Louie Toma

[investors@kairospharma.com](mailto:investors@kairospharma.com)

Source: Kairos Pharma, Ltd